NPS-2143
 | |
| Identifiers | |
|---|---|
| |
| CAS Number |
324523-20-8  |
| PubChem (CID) | 6918446 |
| IUPHAR/BPS | 716 |
| ChemSpider | 5293643 |
| ECHA InfoCard | 100.230.440 |
| Chemical and physical data | |
| Formula | C24H25ClN2O2 |
| Molar mass | 408.919 |
| 3D model (Jmol) | Interactive image |
| |
| |
NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyroid hormone.[1] Calcilytic drugs have been researched as potential treatments for osteoporosis, and as the first such compound developed, NPS-2143 is still widely used in research into the CaSR receptor as well as design of newer calcilytic agents.[2][3][4]
See also
References
- ↑ Nemeth EF, Delmar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL, Gowen M, Gleason JG, Bhatnagar PK, Fox J. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. Journal of Pharmacology and Experimental Therapeutics. 2001 Oct;299(1):323-31. PMID 11561095
- ↑ Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Yang Z, Roethke T, Smith BR, Ward KW, Lee J, Keenan RM, Bhatnagar P. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. Journal of Medicinal Chemistry. 2009 Jul 9;52(13):3982-93. doi: 10.1021/jm900364m PMID 19492813
- ↑ Kiefer L, Leiris S, Dodd RH. Novel calcium sensing receptor ligands: a patent survey. Expert Opinion on Therapeutic Patents. 2011 May;21(5):681-98. doi: 10.1517/13543776.2011.568479 PMID 21406038
- ↑ Breitwieser GE. Pharmacoperones and the calcium sensing receptor: exogenous and endogenous regulators. Pharmacological Research. 2014 May;83:30-7. doi: 10.1016/j.phrs.2013.11.006 PMID 24291533
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.